vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes

Topline data from CATT1 Phase 3 trial on track for second half 2026

HIGH POINT, N.C., Sept. 02, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes ("T1D"), today announced that it has entered into a purchase agreement for an $80 million private placement in public equity ("PIPE") financing with leading healthcare institutional investors and the T1D Fund: A Breakthrough T1D Venture, LLC ("T1D Fund"). The PIPE financing is subject to customary closing conditions and is expected to close on or around September 3, 2025.

Investors in the financing include existing investors in the Company: a life sciences-focused institutional investor, Samsara BioCapital, L.P. ("Samsara"), and the T1D Fund. New investors include Trails Edge Capital Partners, and Invus.

TD Cowen and Evercore ISI are acting as lead placement agents for the PIPE financing.

Pursuant to the terms of the purchase agreement, the Company is selling to the investors units consisting of an aggregate of 682,018 shares of the Company's Class A Common Stock and pre-funded warrants to purchase 4,561,714 shares of the Company's Class A Common Stock, with accompanying warrants to purchase an aggregate of 5,243,732 shares of the Company's Class A Common Stock. The purchase price for a unit consisting of one share of Class A Common Stock and an accompanying warrant is $15.265 and the purchase price for a unit consisting of one pre-funded warrant and an accompanying warrant is $15.255. The exercise price of the accompanying warrants is $22.71 per share.

"This financing enables us to continue advancing the development of cadisegliatin, including the CATT1 trial, which is evaluating the potential of cadisegliatin to help reduce the frequency of level 2 and 3 hypoglycemic events and to improve glycemic control in people living with T1D. It will also provide additional runway for the Company following topline data from the ...